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Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway 
diseases. The aim of this investigation was to compare different methods for measuring BDR 
in participants with asthma and COPD and to study to the extent to which BDR was related to 
symptom burden and phenotypic characteristics. 
 
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) was 
measured before and 15 min after 200 μg of salbutamol in 35,628 subjects aged 16 years and 
older from three large international population studies. The subjects were categorised in three 
groups: current asthma (n=2833), COPD (n=1146), and no airway disease (n=31,649). Three 
definitions for flow related (increase in FEV1) and three for volume related (increase in FVC) 
were used.  
 
The prevalence of bronchodilator reversibility expressed as increase FEV1 ≥ 12% and 200 
mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the 
corresponding prevalence was 5.1% in those with no airway disease. In asthma, 
bronchodilator reversibility was associated with wheeze (OR (95% CI): 1.36 (1.04-1.79)), 
atopy (OR 1.36 (1.04-1.79)) and higher FeNO while in COPD neither flow nor volume related 
bronchodilator reversibility was associated with symptom burden, exacerbations or health 
status after adjusting for prebronchodilator FEV1. 
 
Bronchodilator reversibility was at least as common in participants with COPD as those with 
asthma. This indicates that measures of reversibility are of limited value for distinguishing 
asthma from COPD in population studies. In asthma, however, bronchodilator reversibility 






Performing spirometry before and after inhalation of bronchodilators – bronchodilator 
response (BDR) testing - is used as an instrument for diagnosing asthma. In the Global 
Initiative for Asthma (GINA) report an increase of forced expiratory volume in one second 
(FEV1) ≥ 12% and 200 millilitres (mL) from baseline after inhalation of a short acting beta-2-
agonist is one of the recommended diagnostic criteria for asthma.(1)  
 
Bronchodilator reversibility is also common in COPD and 24% patients with moderate to 
severe COPD had an increase in FEV1 (≥ 12% and 200 mL) in the ECLIPSE study. (2) 
Several studies have indicated that bronchodilator reversibility may be an important 
phenotypic and prognostic marker in asthma. (3-6) For COPD it has, however, been less clear 
that having bronchodilator reversibility is related to any specific phenotypic characteristic or 
to be of prognostic value. (2, 7-9) BDR can also be measured as change in FVC and there are 
data indicating that in patients with severe airflow obstruction this volume related 
bronchodilator reversibility could be more relevant than the flow related bronchodilator 
reversibility measured with change in FEV1.(10) 
 
There are many different ways of defining bronchodilator reversibility. Analyses from the  
Burden of Obstructive Lung Disease (BOLD) have shown the 95th percentiles for BDR in 
healthy never smokers to be 12.0% when expressed as increase in FEV1 in % of baseline, 
(11) which fits well with clinical guidelines.(1) The corresponding value for FVC was 10.5%. 
The threshold values for FEV1 and FVC was 10.0% and 9.2%, respectively when reversibility 
was expressed as percentage of the predicted value.  
 
Most studies of bronchodilator reversibility have been based on patient cohort or randomized 
controlled trials. In the present investigation we combined data from three large population 
studies: BOLD, European Community Respiratory Health Survey III (ECRHS III) (12) and 
Global Asthma and Allergy European Network (GA2LEN).(13) These three studies have used 
a similar methodology, cover a large age range and include many geographical regions. 
Findings obtained by combining these three studies would therefore have a high external 
validity. 
 
The aim of this investigation was to compare different definitions of bronchodilator 
reversibility in participants with asthma and COPD in comparison with participants without 
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these diseases. A secondary aim was to examine whether bronchodilator reversibility was 
related to symptom burden and phenotypic characteristics in asthma and COPD. 
 
Methodology 
This investigation includes 36,956 subjects aged 16 years and older from the three studies that 
had performed a BDR test (Figure 1) (Table E1).  
 
In this analysis, the subjects were categorized into three groups: 
Current asthma was defined as self-reported physician diagnosed asthma in combination with 
current use of asthmatic medication and/or asthma attack within the last 12 months in ECRHS 
III and GA2LEN and as self-reported physician diagnosed asthma in combination with the 
participant reporting to still having asthma in BOLD. 
COPD was defined as having a post bronchodilator FEV1/FVC below the lower limit of 
normal in combination with a smoking history of at least 10 pack years and no history of ever 
having had asthma. 
No airway disease: was defined as no history of ever having had asthma and not having 
COPD according to the definition above. 
 
Subjects with a history of asthma, but no current asthma were excluded from the main 
analyses leaving 35,628 in the analysis (Figure 1). However, in a separate analysis we also 
studied reversibility in participants with asthma COPD overlap (ACO) which in this 
investigation was defined as having a history of doctor’s diagnosed asthma and a post 
bronchodilator FEV1/FVC below the lower limit of normal in combination with a smoking 
history of at least 10 pack years 
 
Spirometry and bronchodilator reversibility test 
Lung function data were obtained in all subjects with use of the ndd EasyOne Spirometer (ndd 
Medizintechnik AG, Zurich, Switzerland). Lung function was measured before and 15 min 
after administration of 200 μg of salbutamol via metered dose inhaler with spacer. Prediction 
equations derived from the Global Lung Initiative were used to compute predicted FEV1 and 
FVC. (14) Weight and height were measured at the clinic visit and body mass index (BMI) 




The participants were asked to refrain from using short acting beta-2-agonists for at least six 
hours long acting beta-2-agonist for 12 hours and long acting antimuscarinic agents for 24 
hours before performing the spirometry. The spirometry was rescheduled if the participant 
had had a respiratory infection within the previous 4 weeks.  
 
This study included both flow related bronchodilator reversibility defined from change in 
FEV1 and volume related bronchodilator reversibility defined as change in FVC. 
 
Flow related bronchodilator reversibility 
Change in FEV1 > 12 as a percentage of the baseline values; change in FEV1 > 10 expressed in units 
of percent predicted (11) and change in FEV1 >12  as a percentage on the baseline values in 
combination with increase in absolute volume > 200 mL.(1) 
 
Volume related bronchodilator reversibility 
Change in FVC > 10.5 as a percentage of the baseline values;  change in FVC > 9.2 expressed in units 
of percent predicted (11) and change in FVC >10.5 as a percentage on the baseline values in 
combination with increase in absolute volume > 320 mL.(11) 
 
Assessment in participants with current asthma 
The association between bronchodilator reversibility and the following variables was assed: 
wheeze, wheeze in combination with breathlessness, wheeze when not having a cold, 
nocturnal chest tightness, attacks of breathlessness at rest, following activity and attacks of 
nocturnal cough in the last 12 months as well as habitual cough (usually coughing in the 
morning or during daytime and chronic bronchitis (bringing up phlegm at least 3 months per 
year), number of attacks of asthma in the last 3 months and nasal allergy.  
Smoking history was categorized as current, ex- and never-smokers 
Information on allergic sensitisation was obtained through skin prick test. The following 
allergens were included: Dertmatophagoides pteronyssinus, Dertmatophagoides farinae, 
timothy grass, ragweed, cat, Cladosporium herbarum, Alternaria tenuis, Parietaria, 
Cockroach, Olive and Birch. These data were not available in the BOLD study. 
 
Measurement of exhaled nitric oxide (FeNO) was performed using the NIOX MINO 
(Aerocrine, Stockholm, Sweden). These data were only available from the ECRHS III and the 




Assessment in participants with COPD 
The association between bronchodilator reversibility and the following variables was 
assessed: wheeze, wheeze in combination with breathlessness, wheeze when not having a 
cold, in the last 12 months, habitual cough (usually coughing in the morning or during 
daytime and chronic bronchitis (bringing up phlegm at least 3 months per year), and dyspnoea 
assessed with the modified Medical Research Council scale and exacerbations ( having 
breathing problems that got so bad that the subject had to see a health provided or become 
hospitalised.) 
Smoking history was categorized as ex-smokers and current smokers. 
 
Health status was assessed by the SF-12 questionnaire (version 2). The physical (PCS) and 
mental health (MCS) component scores were calculated with higher values indicating better 
health status. (16) This information was only available from the BOLD study. 
 
Statistical analyses 
The prevalence of bronchodilator reversibility in the three groups of participants was 
calculated. Differences between the groups was assessed using Chi squared test and, in order 
to adjust for pre bronchodilator FEV1, multiple logistic regression. Chi squared test and 
multivariable logistic regression was used when analyzing the association between 
bronchodilator reversibility and symptom and phenotypic characteristics in the participants 
with asthma and COPD with and without BDR in the asthma and COPD group. In the 
multivariable models adjustment was made for age, sex, smoking history, prebronchodilator 
FEV1 and study. 
 
Sensitivity analyses 
Sensitivity analyses were done to test if the associations differed between the studies. The association of 
bronchodilator reversibility in participants with current asthma using only participants from ECRHS III 
and GA2LEN and the association to bronchodilator reversibility in COPD only using the BOLD study 








The investigation included 16,776 men and 18,852 women, age 54.1±11.0 years (mean±SD), 
range 16-98 years. There were large differences across the study groups in regard to age, sex 
distribution, smoking history, BMI and lung function (Table 1). 
 
The prevalence of bronchodilator reversibility in subjects with no airway disease, asthma and 
COPD is presented in Table 1. The prevalence of BDR was significantly higher in the asthma 
and COPD group compared to the group without airway disease. The prevalence of 
bronchodilator reversibility was higher for COPD than for asthma for most of the different 
definitions of bronchodilator reversibility used in the analyses. The same pattern was also 
seen when analysing only the ECRHS and GA2LEN populations and only the BOLD survey 
(Table E2 and E3). 
 
The association between bronchodilator reversibility and having asthma or COPD compared 
to those with no airway disease remained significant also after adjustment for 
prebronchodilator FEV1, but the association became stronger for asthma than COPD for all 
the flow related responsiveness variables while no significant difference was found for the 
volume related bronchodilator reversibility definitions between asthma and COPD (Figure 2).  
The absolute increase in FEV1 was higher in the group with asthma with flow related 
bronchodilator reversibility (increase in FEV1 > 12% of baselines) that in the corresponding 
group with COPD (358 mL vs. 295 mL, p<0.0001).  No significant difference in absolute 
increase in FVC was found between the asthma and COPD groups in those with volume 




Participants with asthma that had bronchodilator reversibility had a higher prevalence of most 
symptoms and higher FeNO levels than those having asthma without bronchodilator 
reversibility. Participants with asthma and flow related bronchodilator reversibility were more 
often sensitised to mite and had a higher total IgE than participants with asthma without flow 
related bronchodilator reversibility (Table 2). 
 
Wheeze, allergic sensitisation and higher FeNO were independently associated with flow related 
bronchodilator reversibility after adjustment for prebronchodilator FEV1, age, BMI, smoking history 
9 
 
and study (Table 3). Having habitual cough was negatively associated with flow related BDR. Having 
nocturnal chest tightness, not having nocturnal cough and higher FeNO was independently associated 
with volume related bronchodilator reversibility (Table 3). Younger age and having a BMI under 20 was 
independently associated with flow related bronchodilator reversibility while higher age and male sex 
was related to volume related bronchodilator reversibility. Having flow related bronchodilator 
reversibility (increase in FEV1 > 12% of baseline) was independently associated with having a FeNO ≥ 
25 ppb and allergic sensitisation (OR (95% CI) = 2.36 (1.45-3.83) and 2.08 (1.34-3.24)). 
 
COPD 
The prevalence of bronchodilator reversibility increased with the severity of the airway 
obstruction. The prevalence of bronchodilator reversibility (expressed as change in FEV1 > 
12% of baseline) was 12.0, 27.2 and 39.3% in those with a post bronchodilator FEV1 > 80%, 
80-50% and below < 50% of predicted, respectively (p<0.0001). Participants with COPD and 
bronchodilator reversibility reported more symptoms, more exacerbations, more dyspnea and 
lower quality of life in the physical domain than participants with COPD and no 
bronchodilator reversibility (Table 4). However, all these associations became statistically 
non-significant after adjusting for prebronchodilator FEV1, age, BMI, smoking history and 
study (Table 5). The only exception was a significant independent association between 
reported wheezing when not having a cold and having the combination of an increase in 
FEV1 ≥ 12% and 200 mL. Female sex and higher age were independently associated with 
having an increase in FVC≥ 10.5%. 
 
There was no difference in the association between bronchodilator reversibility and the independent 
variables when bronchodilator reversibility was defined from BDR expressed as percentage of predicted 
instead of percentage of baseline (Table E4 and E5).  
 
Asthma COPD overlap 
The number of participants with ACO was 315. The prevalence of flow related reversibility measured as 
an increase in FEV1 ≥ 12% was 33.6% while the prevalence of volume related reversibility expressed as 
an increase in FVC ≥10.5% was 36.8%. Being reversible was related to lower prebronchodilatory FEV1 






The results remained largely similar when only analyzing association with bronchodilator reversibility 
in participants with current asthma using the ECRHS III and GA2LEN study and analyzing association 
with bronchodilator reversibility in COPD only using the BOLD study. Adjusting for use of inhaled 




The main findings of the investigation were that both flow and volume related bronchodilator 
reversibility was at least as common in participants with smoking related COPD as those with 
current asthma. Among participants with current asthma, bronchodilator reversibility was 
independently associated with having wheeze, atopic sensitisation and higher FeNO. Among 
those with COPD reversibility was associated with more symptoms and lower health status 
but these association became statistically non-significant after adjusting for prebronchodilator 
FEV1. 
 
This analysis is to our knowledge the largest study ever that examines clinical correlates of 
bronchodilator reversibility. We show that, 17% of those with asthma and 18% of those with 
COPD had an increase of FEV1 of at least 12% and 200 mL after bronchodilation. This 
accords with previous studies showing that bronchodilator testing is not useful for 
distinguishing between asthma and COPD. (17) Previous work shows that only a minority of 
patients with asthma have BDR (18-20) and the prevalence of bronchodilator reversibility for 
COPD in our study is fairly well in line with what was found in the ECLIPSE study where the 
corresponding prevalence was 24%. (2) Bronchodilator reversibility was strongly related to 
prebronchodilator lung function. When adjusting for prebronchodilator FEV1 flow related 
bronchodilator reversibility was more strongly associated with asthma than COPD whereas no 
significant difference in volume related bronchodilator reversibility was found between 
asthma and COPD. 
 
We found that bronchodilator reversibility was independently associated with IgE 
sensitisation and higher FeNO levels in the group with asthma, suggesting that measuring 
BDR might be of value for phenotypic characterisation of patients with asthma. Higher FeNO 
levels is a marker of type 2 inflammation, frequently used as an indicator of responsiveness to 
inhaled corticosteroids (21). Our findings are in accordance with one study in asthma that 
found that bronchodilator reversibility was associated with being more responsive to inhaled 
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corticosteroids. (6) Studies have also reported that patients with asthma with bronchodilator 
reversibility are more likely to have difficult to control asthma. (3-5). In the present study, we 
found no association between reported attacks of asthma in the last 3 months and 
bronchodilator reversibility but BDR was associated with having wheeze suggesting a 
relationship with less well controlled asthma. 
 
In the unadjusted analyses, COPD patients with bronchodilator reversibility had a higher 
prevalence of wheeze, dyspnea, exacerbations and lower health status. However, this 
association is largely related to both reversibility and symptoms being more common in those 
with low lung function Almost all of these associations became statistically non-significant 
after adjusting for prebronchodilator FEV1. This has been seen in with several other studies 
showing no association between bronchodilator reversibility and prognosis in COPD when 
baseline lung function is taken into account. (2, 7-9) There are, however, some exceptions. In 
one analysis of ECLIPSE, COPD patients with bronchodilator reversibility had a faster 
decline in FEV1 (22) in a large Spanish study higher reversibility was associated with lower 
risk of hospitalisations (23) and in another study bronchodilator reversibility was weakly but 
statically significantly associated with sputum eosinophils count in COPD. (24) 
 
In the present study was no difference between COPD with and without bronchitis, COPD 
with and without frequent exacerbations or COPD patient that were exsmokers or current 
smokers in the adjusted analyses. Apart from this we have, however, no phenotypic 
information on the participants with COPD. 
 
Bronchodilator reversibility is usually defined based on the relative change in FEV1 from the 
baseline value. An alternative way is to measure BDR as a change expressed as percent 
predicted, which potentially decreases the influence of baseline lung function (10, 25). We 
show, however, that both measures are highly dependent on prebronchodilator lung function. 
There was also no difference in the association between bronchodilator reversibility with 
symptoms and phenotypic characteristics in the asthma group between the two methods.   
 
Volume related bronchodilator reversibility was more common in COPD than asthma. This 
was also found after adjusting for prebronchodilator FEV1. Quanjer et al found the 
bronchodilator response to FVC increased with the level of airflow obstruction. They 
suggested that volume related response may be more clinically relevant than increase in FEV1 
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in patients with severe airflow obstruction. (10) In the present study, however, neither flow 
related nor volume related bronchodilator reversibility were independently associated with 
symptom burden, health status or dyspnea in the COPD population. 
 
The study has a high external validity as it is based on participants from the general 
population from different parts of the world. The method for testing BDR and assessment of 
symptoms was similar in all three studies. There are, however, limitations that should be taken 
into account. The definition of asthma was based on self-reported diagnosis, attacks and 
medication and the definition of COPD in this study excluded all subjects with a history of 
asthma as well as participants with non-smoke related COPD. The reason for this is that we 
wanted to create two distinct disease groups with no overlap. A separate analysis was, 
however, done in the group with asthma COPD overlap. This group had a higher prevalence 
of reversibility than those with asthma and COPD alone. As in the COPD group reversibility 
was not associated with any clinical variables, but this might be due to the small number of 
participants with ACO in the present investigation. The dose of salbutamol in the range with 
what is recommended in GINA (1) but lower than what has been recommended in other 
guidelines.(26) On the other hand the definitions used for bronchodilator responsiveness was 
based on BDR test used in the present analysis. (11)  
 
The definition of volume related reversibility in this study may lack precision, as FVC is 
dependent on both flow and volume. Another limitation is that some of the variable studied 
such as IgE sensitisation was only available in a small subset of those with COPD and 
therefore not analysed in this group of participants.  Only one BDR test was performed and 
there is a well-known between day variability in the classification of the patients as reversible 
or not.(9) Hence, the clinical usefulness of the test in an individual patient rather than a 
population is likely to be even lower than suggested here. 
 
We conclude that both flow and volume related bronchodilator reversibility were at least as 
common in participants with smoking related COPD as those with asthma. This indicates that 
measures of reversibility are of limited value for distinguishing asthma from COPD. In 
asthma, however, BDR testing may be a phenotypic marker indicating IgE sensitisation and 
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Table 1 Characteristics and prevalence of bronchodilator reversibility (% and mean±SD). 
 





















Characteristics       
Female 53.0 63.1 <0.0001 26.4 <0.0001 <0.0001 
Age 54±11 53±12 <0.0001 60±11 <0.0001 <0.0001 
Smoking history   <0.0001  <0.0001 <0.0001 
   never 61.2 54.6  0   
   ex 21.8 30.4  40.9   
   current 17.0 15.1  59.1   
BMI   <0.0001  <0.0001 <0.0001 
   <20 8.3 5.3  14.8   
   20-25 33.6 29.6  37.4   
   >25-30 35.3 32.2  32.8   
   >30 22.8 32.9  15.0   
FEV1 pre % of predicted 87±18 78±21 <0.0001 65±20 <0.0001 <0.0001 
FVC pre % of predicted 90±18 88±18 <0.0001 87±20 <0.0001 0.58 
FEV1/FVC pre  % 77±7 69±13 <0.0001 57±10 <0.0001 <0.0001 
FEV1 post % of predicted 89±18 82±21 <0.0001 69±20 <0.0001 <0.0001 
FVC post % of predicted 90±18 90±18 >0.99 92±20 0.001 0.001 
FEV1/FVC post  % 79±7 73±12 <0.0001 58±9 <0.0001 <0.0001 
Flow response       
ΔFEV1> 12% from 
baseline 
5.9 20.2 <0.0001 24.5 <0.0001 <0.0001 
ΔFEV1 > 10% of 
predicted 
8.9 25.8 <0.0001 29.8 <0.0001 0.10 
ΔFEV1> 12% and 200 
mLfrom baseline 
5.1 17.3 <0.0001 18.4 <0.0001 0.39 
Volume response       
ΔFVC > 10.5% from 
baseline 
5.3 15.8 <0.0001 25.2 <0.0001 <0.0001 
ΔFVC > 9.2% of 
predicted 
10.7 22.8 <0.0001 31.6 <0.0001 <0.0001 
ΔFVC> 10.5% and 320 
mL from baseline  





Table 2 Comparison between participants with asthma that have or do not have 
bronchodilator reversibility (% and geometric mean (95% confidence interval)). 
 










Wheeze 72.8 81.5 <0.0001 72.9 81.8 <0..0001 
Wheeze and breathlessness 55.1 63.9 <0.0001 55.8 62.7 0.008 
Wheeze when no cold 44.4 47.5 0.18 44.8 49.0 0.12 
Nocturnal chest tightness* 41.2 51.0 0.10 40.4 57.0 <0.0001 
Breathlessness at rest* 26.0 33.8 0.02 26.2 36.0 0.02 
Breathless after effort* 54.2 61.4 0.06 53.6 64.4 0.02 
Nocturnal breathlessness* 26.6 36.2 0.006 26.6 36.3 0.02 
Nocturnal cough* 55.5 51.0 0.24 55.8 47.1 0.052 
Habitual cough 49.0 47.0 0.39 47.7 50.4 0.31 
Chronic bronchitis 23.9 29.6 0.006 22.4 34.5 <0.0001 
Asthma attacks in last 3 
months* 
  0.99   0.96 
  0 61.9 62.0  62.0 61.6  
  1 17.1 17.2  17.2 16.5  
  2 or more 21.0 20.8  20.8 21.8  
Nasal allergy* 65.7 62.2 0.35 66.9 56.3 0.01 
IgE sensitisation**       
  Pets** 51.0 58.0 0.09 52.7 50.4 0.63 
  Mite** 33.9 42.4 0.03 35.3 35.8 0.91 
  Pollen** 54.6 56.0 0.74 56.0 50.4 0.24 
  Any** 70.1 75.1 0.18 72.3 67.0 0.22 
Total IgE** 64 (59-71) 108 (90-131) <0.0001 68 (62-74) 80 (59-108) 0.28 
FeNO*** 20 (19-21) 25 (22-29) 0.001 20 (19-21) 24 (20-28) 0.04 
 
*data available from 1321 subjects 
** data available from 1215 subjects 





Table 3 Determinants of bronchodilator reversibility in subject with asthma measured as adjusted* odds 
ratio (95 % confidence interval) (Statistically significant associations are marked with bold font) 
 
 ΔFEV1 ΔFVC 
 ≥12% ≥12% + 200mL ≥10.5% ≥10.5% +320mL 
Age per 10 year 0.90 (0.82-0.99) 0.82 (0.75-0.91) 1.23 (1.11-1.37) 1.08 (0.96-1.22) 
Female 1.19 (0.95-1.50) 0.99 (0.79-1.25) 1.19 (0.91-1.54) 0.72 (0.55-0.95) 
Smoke history     
   never 1 1 1 1 
   ex 0.96 (0.74-1.24) 1.01 (0.78-1.31) 1.05 (0.79-1.41) 1.15 (0.84-1.57) 
   current 0.75 (0.55-1.01) 0.78 (0.57-1.06) 1.06 (0.76-1.06) 1.08 (0.75-1.06) 
BMI     
   <20 0.60 (0.37-0.97) 0.51 (0.31-0.85) 0.61 (0.36-1.06) 0.60-(0.33-1.06) 
   20-25 1 1 1 1 
   >25-30 0.98 (0.75-1.29) 1.06 (0.81-1.40) 1.10 (0.80-1.52) 1.06 (0.76-1.48) 
   >30 1.06 (0.81-1.38) 1.06 (0.81-1.40) 1.31 (0.96-1.79) 1.17 (0.84-1.64) 
Wheeze 1.33 (1.02-1.73) 1.36 (1.04-1.79) 1.42 (1.04-1.92) 1.19 (0.86-1.64) 
Wheeze  and 
breathlessness 
1.17 (0.94-1.46) 1.16 (0.93-1.45) 1.10 (0.85-1.42) 1.02 (0.78-1.33) 
Wheeze not having a cold 1.05 (0.84-1.31) 1.10 (0.88-1.38) 1.16 (0.90-1.49) 1.08 (0.82-1.42) 
Nocturnal chest tightness 1.32 (0.93-1.86) 1.35 (0.6-1.91) 2.31 (1.50-3.55) 2.25 (1.44-3.52) 
Beathless at rest 1.28 (0.89-1.86) 1.28 (0.88-1.86) 1.48 (0.95-2.31) 1.65 (1.04-2.60) 
Breathless after effort 0.92 (0.64-1.31) 0.87 (0.61-1.24) 1.08 (0.70-1.68) 1.32 (0.83-2.10) 
Nocturnal brathlessness 1.14 (0.79-1.66) 1.12 (0.77-1.63) 1.19 (0.76-1.88) 1.25 (0.78-1.99) 
Nocturnal cough 0.84 (0.59-1.20) 0.82 (0.58-1.17) 0.64 (0.42-0.98) 0.59 (0.38-0.93) 
Chronic cough 0.74 (0.59-0.92) 0.71 (0.57-0.88) 0.86 (0.67-1.10) 0.96 (0.74-1.25) 
Chronic bronchitis 0.85 (0.67-1.09)1 0.90 (0.76-0.92) 1.15 (0.88-1.50) 1.12 (0.84-1.50) 
Asthma attacks in last 3 
months 
    
  0 1 1 1 1 
  1 1.13 (0.70-1.82) 1.15 (0.72-1.86) 1.42 (0.80-2.52) 1.38 (0.75-2.53) 
  2 or more 0.92 (0.72) 0.85 (0.54-1.33) 1.03 (0.60-1.75) 1.13 (0.66-1.96) 
Nasal allergy 1.15 (0.79-1.66) 1.12 (0.77-1.62) 0.84 (0.54-1.29). 0.79 (0.50-1.25) 
IgE sensitisation     
  Pollen 1.80 (1.22-2.67) 1.54 (1.03-2.31) 1.44 (0.90-2.29) 1.57 (0.94-2.60) 
  Mite 1.91 (1.30-2.81) 2.00 (1.36-2.93) 1.58 (0.99-2.539 1.69 (1.04-2.76) 
  Pets 1.56 (1.04-2.34) 1.82 (1.23-2.69) 1.60 (0.98-2.59) 1.29 (0.80-2.11) 
  Any 2.19 (1.37-3.51= 1.36 (1.04-1.79) 1.57 (0.93-2.64) 1.42 (0.82-2.45) 
Total IgE (per log unit) 1.50 (1.12-2.03) 1.53 (1.13-2.06) 0.94 (0.65-1.36) 1.01 (0.68-1.49) 
FeNO (per log unit) 5.27 (2.47-11.3) 5.02 (2.36-10.7) 3.61 (1.48-8.82) 3.80 (1.49-9.64) 
FEV1 pre % of predicted 0.94 (0.93-0.95) 0.95 (0.95-0.96) 0.94 (0.94-0.95) 0.97 (0.96-0.98) 
FVC pre  % of predicted 0.96 (0.95-0.97) 0.97 (0.96-0.98) 0.94 (0.93-0.95) 0.96 (0.96-0.97) 
 




Table 4 Comparison between participants with COPD that have or do not have bronchodilator 
reversibility. 
 










Wheeze 37.3 52.0 <0.0001 40.2 45.0 0.16 
Wheeze  and breathlessness 15.3 30.6 <0.0001 17.2 25.7 0.002 
Wheeze when no cold 17.2 28.8 <0.0001 18.8 24.3 0.047 
Habitual coughing 39.3 47.0 0.02 40.6 44.3 0.28 
Chronic bronchitis 18.7 26.2 0.007 18.8 26.3 0.008 
Exacerbations   0.008   0.13 
  0 94.9 89.6  94.3 91.0  
  1 1.4 2.3  1.3 2.8  
  2 or more 3.7 8.1  4.5 6.3  
MRC   <0.0001   0.001 
   0 60.4 43.5  58.9 46.2  
   1 24.6 31.3  25.8 29.4  
   2 4.3 4.9  4.4 5.5  
   3 or 4 10.6 20.3  10.9 18.9  
SF12*       
   mcs12 50.5±10.2 49.2±11.0 0.12 50.5±10.0 49.6±11.3 0.32 
   pcs12 45.1±10.2 42.2±11.0 0.0006 45.0±10.2 42.6±11.1 0.005 
 




Table 5. Determinants of bronchodilator reversibility in subject with COPD measured as adjusted* odds 
ratio (95 % confidence interval) (Statistically significant associations are marked with bold font). 
 
 
 ΔFEV1 ΔFVC 
 ≥12% ≥12% + 200mL ≥10.5% ≥10.5% +320mL 
Female 1.30 (0.92-1.84) 0.88 (0.61-1.28) 1.21 (1.04-1.40) 1.15 (0.99-1.33) 
Age 1.10 (0.94-1.28) 0.95 (0.81-1.11) 1.61 (1.16-2.23) 1.11 (0.79-1.56) 
Current smoking 0.97 (0.69-1.35) 0.93 (0.66-1.31) 1.14 (0.82-1.58) 1.03 (0.74-1.43) 
BMI     
   <20 0.65 (0.41-1.04) 0.53 (0.32-0.90) 0.82 (0.52-1.29) 0.75 (0.47-1.21) 
   20-25 1 1 1 1 
   >25-30 1.32 (0.90-1.92) 1.30 (0.89-1.90) 1.19 (0.83-1.71) 1.14 (0.79-1.64) 
   >30 1.30 (0.82-2.07) 1.27 (0.80-2.03) 1.46 (0.94-2.27) 1.42 (0.91-2.21) 
Wheeze 1.23 (0.90-1.70) 1.21 (0.88-1.68) 0.89 (0.65-1.20) 0.98 (0.72-1.34) 
Wheeze  and 
breathlessness 
1.41 (0.98-2.03) 1.31 (0.90-1.91) 1.06 (0.74-1.52) 1.16 (0.80-1.67) 
Wheeze when no cold 1.43 (0.99-2.06) 1.56 (1.08-2.26) 1.10 (0.77-1.57) 1.17 (0.81-1.69) 
Habitual coughing 1.06 (0.77-1.45) 0.97 (0.69-1.34) 0.92 (0.68-1.25) 0.94 (0.69-1.28) 
Chronic bronchitis 1.01 (0.70-1.47) 0.95 (0.64-1.39) 1.20 (0.85-1.70) 1.29 (0.91-1.84) 
Exacerbations     
  0 1 1 1 1 
  1 0.94 (0.30-2.90) 0.88 (0.26-2.96) 1.38 (0.49-3.91) 1.53 (0.53-4.37) 
  2 or more 1.16 (0.58-2.30) 0.65 (0.30-1.39) 0.87 (0.44-1.73) 1.04 (0.52-4.37) 
MRC     
   0 1 1 1 1 
   1 1.10 (0.75-1.63) 1.13 (0.76-1.67) 0.98 (0.67-1.42) 0.96 (0.65-1.42) 
   2 0.70 (0.31-1.56) 0.67 (0.29-1.57) 0.91 (0.43-1.93) 0.71 (0.32-1.60) 
   3 or 4 0.84 (0.51-1.39) 0.69 (0.40-1.17) 0.99 (0.61-1.61) 1.02 (0.62-1.67) 
SF12*     
   mcs12 0.99 (0.97-1.004) 0.99 (0.98-1.01) 1.00 (0.99-1.02) 0.99 (0.98-1.01) 
   pcs12 1.01 (0.99-1.03) 1.01 (0.99-1.02) 0.99 (0.98-1.01) 1.01 (0.99-1.03) 
FEV1 pre %of predicted 0.94 (0.93-0.95) 0.96 (0.95-0.97) 0.96 (0.95-0.97) 0.97 (0.96-0.98) 
FVC pre  % of predicted 0.96 (0.95-0.97) 0.98 (0.97-0.98) 0.95 (0.94-0.96) 0.96 (0.96-0.97) 
 








Figure 1. Study design 
 
 
Figure 2. Association between bronchodilator responsiveness and asthma (circle) and COPD 
(triangle) with participants without airway disease as the reference group. The association is 








































Table E1. Characteristics and design of the three cohort studies 
 
 European Community 
Health Survey III 
(ECRHS III) 
Global Allergy and 
Asthma European 
Network 
 (GA2LEN) survey 
Burden of Obstructive 
Lung Disease 
(BOLD) 
Design Second follow up of 
general population 
based survey 









Age span 39-67 years 16-76 years 40 and above 
Year 2010-2014 2008-2009 2003-2017 
Centres 23 centres in Europe 
and one in Australia 
15 centres all in 
Europe 
34 centres all around 
the world 






















Table E2 Characteristics and prevalence of bronchodilator reversibility (% and mean±SD) in 
the European Community Health Survey III (ECRHS III) and Global Allergy and Asthma 
European Network (GA2LEN) surveys. 
. 





















Characteristics       
Female 52.4 60.5 <0.0001 42.0 <0.0001 <0.0001 
Age 52±10 49±13 <0.0001 58±8 <0.0001 <0.0001 
Smoking history   <0.0001  <0.0001 <0.0001 
   never 46.0 50.5  0   
   ex 34.7 36.2  55.5   
   current 19.3 13.3  44.5   
BMI   <0.0001  <0.0001 <0.0001 
   <20 3.7 3.6  0.8   
   20-25 35.6 35.2  31.4   
   >25-30 39.8 33.9  40.7   
   >30 20.9 27.2  17.1   
FEV1 pre % of predicted 96±18 84±18 <0.0001 74±17 <0.0001 <0.0001 
FVC pre % of predicted 99±15 93±15 <0.0001 93±17 <0.0001 >0.99 
FEV1/FVC pre  % 77±7 72±10 <0.0001 61±7 <0.0001 <0.0001 
FEV1 post % of predicted 98±14 88±17 <0.0001 78±16 <0.0001 <0.0001 
FVC post % of predicted 98±13 95±14 <0.0001 98±17 >0.99 0.047 
FEV1/FVC post  % 79±6 75±10 <0.0001 62±5 <0.0001 <0.0001 
Flow response       
ΔFEV1> 12% from 
baseline 
3.2.  15.0 <0.0001 19.3 <0.0001 <0.0001 
ΔFEV1 > 10% of 
predicted 
5.2 20.0 <0.0001 28.6 <0.0001 0.03 
ΔFEV1> 12% and 200 
mLfrom baseline 
3.0 14.1 <0.0001 16.8 <0.0001 0.43 
Volume response       
ΔFVC > 10.5% from 
baseline 
2.9 10.7 <0.0001 20.7 <0.0001 0.002 
ΔFVC > 9.2% of 
predicted 
6.5 17.2 <0.0001 29.4 <0.0001 0.001 
ΔFVC> 10.5% and 320 
mL from baseline  






Table E3 Characteristics and prevalence of bronchodilator reversibility (% and mean±SD) in 
the Burden of Obstructive Lung Disease (BOLD) survey 
. 





















Characteristics       
Female 53.1 65.4 <0.0001 24.6 <0.0001 <0.0001 
Age 54±11 56±11 <0.0001 60±11 <0.0001 <0.0001 
Smoking history   <0.0001  <0.0001 <0.0001 
   never 64.9 58.2  0   
   ex 18.7 25.3  39.2   
   current 16.4 16.6  60.8   
BMI   <0.0001  <0.0001 <0.0001 
   <20 9.4 6.8  16.4   
   20-25 33.1 24.6  38.1   
   >25-30 34.2 30.7  31.9   
   >30 23.3 37.9  13.6   
FEV1 pre % of predicted 85±18 72±23 <0.0001 64±20 <0.0001 <0.0001 
FVC pre % of predicted 88±18 83±20 <0.0001 87±21 0.02 <0.0001 
FEV1/FVC pre  % 77±7 69±13 <0.0001 57±10 <0.0001 <0.0001 
FEV1 post % of predicted 87±18 77±22 <0.0001 68±20 <0.0001 <0.0001 
FVC post % of predicted 88±18 85±19 >0.99 91±20 <0.0001 <0.0001 
FEV1/FVC post  % 79±7 71±12 <0.0001 58±9 <0.0001 <0.0001 
Flow response       
ΔFEV1> 12% from 
baseline 
6.6 24.8 <0.0001 25.1 <0.0001 0.84 
ΔFEV1 > 10% of 
predicted 
9.8 30.9 <0.0001 30.0 <0.0001 0.62 
ΔFEV1> 12% and 200 
mLfrom baseline 
5.6 20.0 <0.0001 18.6 <0.0001 0.38 
Volume response       
ΔFVC > 10.5% from 
baseline 
5.9 20.3 <0.0001 25.7 <0.0001 0.002 
ΔFVC > 9.2% of 
predicted 
11.7 27.6 <0.0001 31.8 <0.0001 0.02 
ΔFVC> 10.5% and 320 
mL from baseline  






Table E4. Determinants of bronchodilator reversibility in subject with asthma measured as adjusted* 
odds ratio (95 % confidence interval) 
 
 ΔFEV1 ΔFVC 
  > 10% of predicted > 9.2% of predicted 
Wheeze 1.29 (1.02-1.63) 1.36 (1.05-1.73) 
Wheeze  and breathlessness 1.24 (1.02-1.52) 1.08 (0.78-1.19) 
Wheeze not having a cold 1.05 (0.86-1.28) 1.08 (0.88-1.34) 
Nocturnal chest tightness 1.24 (0.91-1.68) 1.73 (1.25-2.40) 
Beathless at rest 1.18 (0.84-1.65) 1.40 (0.99-1.98) 
Breathless after effort 0.84 (0.61-1.15) 1.06 (0.76-1.48) 
Nocturnal brathlessness 1.11 (0.80-1.56) 1.20 (0.85-1.71) 
Nocturnal cough 0.87 (0.63-1.19) 0.82 (0.59-1.13) 
Chronic cough 0.77 (0.63-0.93) 0.91 (0.75-1.12) 
Chronic bronchitis 0.93 (0.74-1.17) 1.36 (1.08-1.69) 
Asthma attacks   
  0 1 1 
  1 0.97 (0.63-1.50) 1.48 (0.96-2.30) 
  2 or more 1.03 (0.70-1.52) 0.99 (0.65-1.50) 
Nasal allergy 1.16 (0.83-1.60) 0.89 (0.64-1.25) 
IgE sensitisation   
  Pollen 1.59 (1.11-2.27) 1.34 (0.93-1.93) 
  Mite 1.80 (1.28-2.53) 1.37 (0.96-1.97) 
  Pets 1.70 (1.20-2.39) 1.59 (1.11-2.28) 
  Any 2.07 (1.37-3.13) 1.48 (0.99-2.20) 
Total IgE (log increase) 1.26 (0.97-1.64) 0.98 (0.75-1.28) 
FeNO (log increase) 5.43 (2.80-10.5) 3.30 (1.67-6.53) 
 





Table E5. Determinants of bronchodilator reversibility in subject with COPD measured as adjusted* 
odds ratio (95 % confidence interval) 
 
 ΔFEV1 ΔFVC 
  > 10% of predicted > 9.2% of predicted 
Wheeze 1.21 (0.90-1.62) 0.97 (0.74-1.28) 
Wheeze  and breathlessness 1.31 (0.93-1.85) 1.17 (0.84-1.63) 
Wheeze when no cold 1.35 (0.96-1.92) 1.12 (0.80-1.56) 
Habitual coughing 1.12 (0.84-1.51) 0.08 (0.75-1.30) 
Chronic bronchitis 0.88 (0.62-1.25) 1.17 (0.85-1.62) 
Exacerbations   
  0 1 1 
  1 0.98 (0.33-2.91) 0.99 (0.35-2.78) 
  2 or more 1.44 (0.74-2.79) 0.75 (0.39-1.45) 
MRC   
   0 1 1 
   1 1.07 (0.74-1.54) 1.00 (0.71-1.41) 
   2 0.79 (0.37-1.54) 1.14 (0.57-2.26) 
   3 or 4 0.92 (0.57-1.49)  
SF12*   
   mcs12 0.99 (0.97-1.01) 0.99 (0.98-1.01) 
   pcs12 1.01 (0.99-1.02) 1.00 (0.98-1.02) 
 
*Adjusted by sex, age, BMI, smoking, prebronchodilator FEV1 (% pred) and study 
 
 
 
 
